ClinicalTrials.gg
CompletedNCT06901830Updated Jun 29, 2026

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery

A Phase 2 interventional study of YZJ-4729 and Placebo Comparator: Saline in Pain, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 21 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Pain with a site in China — 65 open to participants now, 71 under way, 2 of them phase 3. Pain · China.

Enrollment
85th of 210
150 · median 120
Started
2025
with 34 others
Phase 2
18 of 245
4 open now
Registered
185th of 245
by date

Among the 245 studies in Pain with a site in China, this one is the 85th largest by enrollment of the 210 interventional ones that give a count, is one of 35 that started in 2025, is one of 18 in phase 2, and was the 185th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

65 of the 245 studies in Pain with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Pain with a site in China, or all of them as a file.
02

Study summary

The primary objective is to evaluate the analgesic efficacy and safety of IV YZJ-4729 Tartrate Injection in patients with acute postoperative pain following Orthopedic surgery

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written
  2. ≥18.0 kg/m2 and ≤28.0 kg/m2
  3. Experiences a pain intensity rating of moderate to severe acute pain following orthopedic surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery

Exclusion criteria

Exclusion Criteria:

  1. Opioid allergy
  2. Nervous system diseases (e.g. epilepsy)
  3. Psychiatric disorders (e.g. depression)
  4. History of difficult airways
  5. Random blood glucose ≥11.1 mmol/L
  6. Subjects with systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg or systolic blood pressure \< 90 mmHg
  7. Abnormal pulse oxygen saturation (SpO2 \<92 %)
  8. Abnormal liver function or renal function
  9. Used agents that could affect the analgesic response
  10. Used agents that could affect drug metabolism
  11. Has previously participated in another YZJ-4729 clinical study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Experimental Group 1

    Drug: YZJ-4729

  • Experimental
    Experimental Group 2

    Drug: YZJ-4729

  • Experimental
    Experimental Group 3

    Drug: YZJ-4729

  • Placebo comparator
    Placebo Comparator

    Drug: Placebo Comparator: Saline

  • Active comparator
    Active Comparator

    Drug: Active Comparator: Morphine

Interventions

06

What researchers measure

Primary outcomes

  1. The sum of pain intensity differences in pain score over 48 hours at rest

    Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NRS), with higher numbers indicating a higher pain intensity, administered over 48 hours.

    Time frame: 48 hours

Secondary outcomes

  1. The time of first using of rescue analgesics

    Time frame: 0-48 hours

  2. The proportion of subjects using rescue analgesics

    Time frame: 0-48 hours

  3. The number of times for rescue analgesics using

    Time frame: 0-48 hours

  4. The cumulative dose used of rescue analgesics

    Time frame: 0-48 hours

  5. The resting Sum of Pain Intensity Differences Over 12,24,24~48

    Time frame: 0-48 hours

  6. The active Sum of Pain Intensity Differences Over 12,24,48,24~48

    Time frame: 0-48 hours

  7. Participant satisfaction scores for analgesia treatment

    Participants recalled the postoperative analgesia effect and rated their satisfaction on a scale of 1 to 5, with 1 representing dissatisfied and 5 representing very satisfied

    Time frame: 48 hours

  8. Investigator satisfaction scores for analgesia treatment

    Postoperative analgesia was evaluated by investigators. The scale ranges from 1 to 5, with 1 being dissatisfied and 5 being very satisfied

    Time frame: 48 hours

07

Study locations

21 sites
  • The Third Xiangya Hospital of Central South University
    Changsha, China
  • Chengdu Second People's Hospital
    Chengdu, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • The Third People's Hospital of Chengdu
    Chengdu, China
  • The First Hospital of Jilin University
    Ch’ang-ch’un, China
  • Dalian University Affiliated Zhongshan Hospital
    Dalian, China
  • Dongguan People's Hospital
    Dongguan, China
  • The First Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, China
  • The Second People's Hospital of Hefei
    Hefei, China
  • Jinhua Central Hospital
    Jinhua, China
  • Mianyang Central Hospital
    Mianyang, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
  • Zhongda Hospital Southeast University
    Nanjing, China
  • Ningbo Medical Center Lihuili Hospital
    Ningbo, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, China
  • The Second Affiliated Hospital of Fujian Medical University
    Quanzhou, China
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • Shanghai First People's Hospital
    Shanghai, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, China
  • Suzhou University Affiliated Second Hospital
    Suzhou, China
  • Henan Provincial People's Hospital
    Zhengzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Dec 2025, 6 months.

Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 30, 2025
StartActual
May 23, 2025
Primary completionActual
Dec 6, 2025
CompletionActual
Dec 18, 2025
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06901830
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
May 23, 2025
Primary completion
Dec 6, 2025
Completion
Dec 18, 2025
Last update
Jun 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Susineridine

Start the discussion